Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

Here are three dirt cheap, ultra-high-yield dividend stocks to buy right now. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now ...

Currently, AbbVie’s Ubrelvy (ubrogepant) and Pfizer’s Zavzpret (zavegepant) and Nurtec (rimegepant) are available for acute treatment in the US. To intensify the competition, novel drug combinations ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, ...